Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SGLT2 inhibitor on proteinuria in diabetic patients
NCT03573102Phase 4Unknown
- Start
- Jun 2018
- Primary completion
- Jun 2020
- Countries
- 1
01
Overview
Phase 4 trial in diabetic nephropathy (DN). Primary endpoint: Decrease in proteinuria at 6 months. Status: unknown.
02
Conditions
diabetic nephropathy (DN)
Beyond the preview
Go deeper on NCT03573102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03573102.